This product is intended as a research chemical only. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, or cosmetic.
Peptides
Retatrutide (10 vials/Kit)
Quantity: Kit (10 vials)
Retatrutide is a GGG tri-agonist that uniquely targets GLP-1 and GIP receptors, similar to standard GLP-1 agonists, but also activates the glucagon receptor. This additional receptor interaction enhances glucagon production, leading to the breakdown of stored fats and glycogen, thereby increasing basal metabolism for more consistent fat loss. Its actions on GLP-1 and GIP receptors promote delayed gastric emptying and appetite control, providing a comprehensive approach to obesity research distinct from older GLP-1 agonists. Please note, this product is intended for research purposes only and is not for human or animal consumption.
SKU: N/A
Category: Peptides
Description
Additional information
MG | 6MG, 12MG |
---|
Reviews (0)
Only logged in customers who have purchased this product may leave a review.
Related products
-
Peptides
Ipamorelin (10 vials/Kit)
$80.00 Select options This product has multiple variants. The options may be chosen on the product page -
Peptides
Semaglutide (10 vials/Kit)
$120.00 – $200.00 Select options This product has multiple variants. The options may be chosen on the product page -
Peptides
Tesamorelin (10 vials/Kit)
$180.00 Select options This product has multiple variants. The options may be chosen on the product page -
Peptides
BPC 157 (10 vials/Kit)
$35.00 – $60.00 Select options This product has multiple variants. The options may be chosen on the product page
Reviews
There are no reviews yet.